Swedish hospital evaluating pyrosequencing platform
The Department of Pathology at Uppsala University Hospital in Sweden is evaluating Biotage's new pyrosequencing platform to detect a genetic biomarker that indicates how well a cancer patient will respond to targetted drug therapies.